Albert Antolin

Dr. Albert Antolin studied Organic Chemistry at Ramon Llull University (Barcelona, Spain). After working two years as an in silico medicinal chemist in the pharmaceutical company Laboratorios Salvat, he moved back to academia to pursue a PhD in Pharmacoinformatics at Pompeu Fabra University (Barcelona, Spain). During his PhD, Dr. Antolin pioneered the application of polypharmacology prediction to chemical biology by uncovering distantly-related off-targets of chemical probes.

After defending his PhD in 2014, Dr. Antolin was awarded a prestigious Marie Curie Fellowship to join the Institute of Cancer Research (ICR), Department of Data Science and Division of Cancer Therapeutics (London, UK) to develop the first objective, quantitative and data-driven resource for the assessment of chemical probes, Probe Miner. Next, Dr. Antolin secured the prestigious Sir Henry Wellcome Postdoctoral Fellowship to explore the polypharmacology of cancer drugs and their implications for precision oncology. In 2021, Dr. Antolin was promoted to ICR Fellow and Junior Team Leader at ICR starting his Systems Chemical Biology Team.

In 2022, first thanks to a prestigious La Caixa Junior Leader Fellowship and later a Miguel Servet Fellowship, Dr. Antolin moved his team to the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) in Barcelona (Spain). In 2025, he and his laboratory were recruited to the Vall d'Hebron Institute of Oncology (VHIO) also in Barcelona. In addition, he continues to be an Honorary Fellow at the ICR.

Having worked in industry and academia, Dr. Antolin is particularly interested in translational research aiming to bridge applied industrial drug discovery with a much-needed understanding of remaining fundamental questions in cancer chemical systems biology.